📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
10 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Annals of the rheumatic diseases · 2015
The Journal of rheumatology · 2014
Objective.To evaluate the humoral immune response to pneumococcal and influenza vaccination in adults with rheumatoid arthritis (RA) receiving certolizumab pegol (CZP).Methods.In this 6-week, single-blind, placebo-controlled trial with optional 6-month open-label extension (NCT00993668), patients were stratified by concomitant methotrexate (MTX) use and randomized to receive CZP 400 mg (loading dose; according to CZP label) or placebo at weeks 0, 2, and 4. Pneumococcal (polysaccharide 23) and influenza vaccines were administered at Week 2. Satisfactory humoral immune response, defined as ≥ 2-fold titer increase in ≥ 3 of 6 pneumococcal antigens and ≥ 4-fold titer increase in ≥ 2 of 3 influenza antigens, were assessed independently 4 weeks after vaccination.Results.Following pneumococcal vaccination, 62.5% of placebo patients and 54.5% of CZP patients without effective titers at baseline achieved a humoral response (difference in proportions was −8.0 percentage points; 95% CI −22.5 to 6.6%). Following influenza vaccination, 61.4% of placebo and 53.5% of CZP patients without effective titers at baseline achieved a humoral response (difference in proportions: −8.0 percentage points; 95% CI −22.9 to 7.0%). In all patients, including those with effective titers at baseline, 58.2% of placebo and 53.3% of CZP patients developed satisfactory pneumococcal titers, and 54.1% of placebo and 50.5% of CZP patients developed satisfactory influenza antibody titers. Vaccine responses to pneumococcal and influenza antigens were reduced similarly in both treatment groups with concomitant MTX use.Conclusion.Humoral immune responses to pneumococcal and influenza vaccination are not impaired when given during the loading phase of CZP treatment in patients with RA. (ClinicalTrials.govNCT00993668).
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Clinical rheumatology · 2021 · Journal Article
Lau CS, Chen YH, Lim K, de Longueville M, et al.
Clinical and translational science · 2020 · Journal Article
Paul S, Marotte H, Kavanaugh A, Goupille P, et al.
RMD open · 2019 · Journal Article
Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, et al.
Arthritis research & therapy · 2017 · Journal Article
Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, et al.
Rheumatology and therapy · 2017 · Journal Article
Fleischmann R, van Vollenhoven RF, Vencovský J, Alten R, et al.
RMD open · 2015 · Journal Article
Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, et al.
RMD open · 2015 · Journal Article
Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, et al.
Annals of the rheumatic diseases · 2015 · Journal Article
Bykerk VP, Cush J, Winthrop K, Calabrese L, et al.
The Journal of rheumatology · 2014 · Clinical Trial, Phase IV
Kivitz AJ, Schechtman J, Texter M, Fichtner A, et al.
Annals of the rheumatic diseases · 2014 · Clinical Trial, Phase III
Landewé R, Braun J, Deodhar A, Dougados M, et al.
Rheumatology and therapy · 2017 · Journal Article
Fleischmann R, van Vollenhoven RF, Vencovský J, Alten R, et al.